142 results about "Diagnostic biomarker" patented technology

The invention relates to a method for acquiring a biomarker for assisting CRLM early diagnosis. The method comprises the following steps: acquiring sequencing data, clinical information and metabonomics characteristics of a CRC sample; evaluating and determining a plurality of differentiated machine learning models; performing classification according to the determined machine learning model, and constructing a CRLM biomarker prediction model; screening candidate biomarkers according to the prediction model; and verifying the candidate biomarker at least according to the tissue slice and the serum sample, and determining a final biomarker.

The present invention discloses the use of extracellular vesicles derived from oligodendrocytes carrying FTH1 in differentiating between multiple system atrophy and Parkinson's disease, belonging to the field of biomedical technology. The present invention utilizes fluorescently labeled CNPase antibodies and FTH1 antibodies to accurately detect extracellular vesicles derived from oligodendrocytes carrying FTH1 in plasma. By detecting the concentration of extracellular vesicles derived from oligodendrocytes carrying FTH1 (FTH1-positive) in plasma, it is possible to accurately distinguish between MSA patients, PD patients, and healthy individuals. This provides a highly effective biomarker for MSA diagnosis, improves the ability to diagnose MSA early and differentiate between MSA and PD, and effectively addresses the complexity and low sensitivity issues faced by traditional diagnostic methods.

The invention belongs to the technical field of gestational diabetes diagnosis marker screening, and particularly relates to a biomarker for predicting or diagnosing gestational diabetes and application of the biomarker. The invention discloses a biomarker for predicting or diagnosing gestational diabetes mellitus, the biomarker is selected from one or more of hypoxanthine, cortisol, dihydrotachysterol and cycloleucine, and more preferably, the biomarker comprises hypoxanthine, cortisol, dihydrotachysterol, (3R, 4R)-D-ketolactone, creatine, cycloleucine and L-hydroorotic acid. The seven biomarkers disclosed by the invention can predict or diagnose gestational diabetes mellitus independently or jointly through plasma detection at the early pregnancy stage, effectively improve the early diagnosis rate of gestational diabetes mellitus and improve disease prognosis, and have clinical use and popularization values.

The application belongs to the field of biochemical detection, and specifically discloses a new use of a GPR18 and other gene detection agent combination and a depression detection reagent. The application of the GPR18 expression level detection agent in the preparation of a major depressive disorder detection product. The expression amount of GPR18, PDK4, NRG1 and EPHB2 in the application actually has high diagnostic efficiency, and can be used as an independent candidate diagnostic biomarker. The accuracy of each as a screening indicator reaches 0.6 to 0.8, reaching the standard of a medium-strength screening indicator, and the accuracy of the combined expression amount indicator as a screening indicator reaches 0.779.

The invention belongs to the technical field of biology, and relates to a proteomics-based adenoid hypertrophy grading diagnosis biomarker and application thereof. Comprising BET1, RPS6KA4, HSPA1A, DPP4, OSTC, MRPL21, CMC4, RPL37, PSPH, PTPRS, MFAP5, KIAA1143, EMC4, ZNF460, ABHD13, SH3BP5L, GPC3, DNAJC19, DTD1, H3-7, MKNK1, MFAP2, WRAP73, IGLV4-69, P4HA1, S100A9, QSOX2, RNF25, RMND5A and MRPS28. The invention further discloses a preparation method of the high-efficiency and high-efficiency biomedical kit. The screened biomarker can accurately diagnose the severity of adenoid hypertrophy in a non-large-area invasive manner, and especially can accurately distinguish severe adenoid hypertrophy from moderate adenoid hypertrophy.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

Featured are methods of identifying (e.g., diagnosing) and / or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and / or liver cancer (e.g., HCC). The methods utilize predictive and / or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and / or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.

The invention belongs to the technical field of medical detection, and particularly relates to a marker for smoke disease diagnosis and application thereof. The invention discloses a marker for smoke disease diagnosis. The marker for smoke disease diagnosis is miRNA (micro Ribonucleic Acid); the miRNA is hsa-miR-4433a-5p, and the nucleotide sequence of the miRNA is as shown in SEQ ID NO. 1 (sequence identifier number 1). Experiments prove that the expression level of hsa-miR-4433a-5p in smoke disease patients is obviously higher than that of hsa-miR-4433a-5p in healthy people, and hsa-miR-4433a-5p can be used as a marker for smoke disease diagnosis. Meanwhile, the marker for smoke disease diagnosis is applied to preparation of the kit, the content of hsa-miR-4433a-5p in serum can be detected through a real-time fluorescent quantitative PCR technology, and the kit has the advantages of being high in sensitivity and accuracy and wide in application prospect.

This invention discloses a lncRNA biomarker associated with AML, characterized in that the lncRNA biomarker is lncRNA FOXN3-AS1, and the nucleotide sequence of lncRNA FOXN3-AS1 is shown in SEQ ID NO: 1. This invention also discloses the application of a detection kit and method in the diagnosis and prognosis of AML. The lncRNA FOXN3-AS1 of this invention, as an auxiliary diagnostic biomarker for clinical detection of AML, has the advantages of simple operation, low cost, and accurate detection, making it suitable for clinical screening. The biomarker provided by this invention can be applied to the preparation of early AML assessment products, which is beneficial for further elucidating the pathogenesis of AML and helps in the discovery of novel small molecule drug targets with potential therapeutic value.

The application relates to a blood biomarker for evaluating and diagnosing Parkinson's disease and an application thereof. The blood biomarker is SERPINA3 and / or alpha-Syn. By using the biomarker as a diagnostic biomarker for Parkinson's disease, early diagnosis of Parkinson's disease can be assisted by detecting the SERPINA3 level and the alpha-Syn level in a blood sample, the trauma is small, the operation is simple, and the method is suitable for most patients and has high patient acceptance; and the SERPINA3 and alpha-Syn levels in the blood sample can be determined by a photochemical luminescence detection method, the detection sensitivity is high, the accuracy is high, and early, efficient and high-precision diagnosis of Parkinson's disease can be realized.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

This invention discloses the application of ESCO1 and NUFIP2 in the diagnosis and treatment of pancreatic cancer, relating to the field of biomedical technology. This invention provides the application of ESCO1 and / or NUFIP2 as pancreatic cancer biomarkers in the preparation of pancreatic cancer diagnostic or prognostic assessment products, and also provides the application of ESCO1 and / or NUFIP2 as drug targets in the screening or preparation of drugs for the prevention and / or treatment of pancreatic cancer. This invention discovers that ESCO1 and NUFIP2 have important biological significance in pancreatic cancer, with NUFIP2 expression regulated by ESCO1, and both expression levels positively correlated with the malignant progression of pancreatic cancer. Therefore, ESCO1 and NUFIP2 can not only serve as potential diagnostic biomarkers and therapeutic targets for pancreatic cancer, but also provide new theoretical basis and research directions for optimizing pancreatic cancer immunotherapy strategies.

The application discloses use of LncRNA00_178, miR-466b-3p and Gucy1b1 as acute lung injury markers or drug targets, and belongs to the technical field of biomarkers and drug targets. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, a miR-466b-3p down-regulator can be used to prepare a pharmaceutical composition for preventing and treating acute lung injury, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The application has the beneficial effects that the application proposes that LncRNA00_178 and miR-466b-3p, and miR-466b-3p and Gucy1b1 have a target binding relationship. LncRNA00_178 can be used as a biomarker for screening or diagnosing acute lung injury, the silence of miR-466b-3p inhibits LPS-induced apoptosis of alveolar epithelial cells, and Gucy1b1 can be used as a drug target to prepare a drug for preventing and / or treating acute lung injury. The data provide new insights for the treatment mechanism of ALI and the identification of specific targets, and provide a new idea for the research and development of new drugs for acute lung injury, and have a wide application prospect.

The invention relates to the technical field of biology, and particularly discloses application of LLPH as a lung cancer diagnosis biomarker and a treatment target spot, an LLPH expression inhibitor is an LLPH gene knockout plasmid and a genetic engineering construct containing sgRNA and a carrier, the LLPH expression inhibitor is suitable for CRISPR / Cas system mediated gene editing, the sgRNA sequence is 5 '-CTAAAGCTTACGGAGTAAG-3', the carrier is pX459M, and the enzyme cutting site is BbsI-BbsI; by detecting the relative expression quantity of LLPH in normal lung bronchial epithelial cells and lung cancer cell lines, it is found that LLPH is highly expressed in the lung cancer cell lines, and it is shown that LLPH is closely related to lung cancer development. The invention can provide a new biomarker for diagnosis of lung cancer. Lung cancer A549 and H1299 cells are used as models, and the LLPH gene is knocked out, so that the in-vitro malignant proliferation capacity of the lung cancer cells A549 and H1299 can be remarkably inhibited, and LLPH can be used as a potential treatment target for inhibiting lung cancer proliferation.

The present application describes miRNAs in the diagnosis and treatment of small fiber neuropathy (SFN).

The invention belongs to the technical field of biomarkers, and particularly relates to a marker for unexplained recurrent spontaneous abortion and application of the marker. The marker is at least one of LARP1, LSM1 and NCBP2 (National Center For Biotechnology Protein). The invention has the following beneficial effects: the expression of six m7G regulatory factors in URSA is abnormal: LSM1 and NUDT16 are up-regulated, and IFIT5, LARP1, NCBP2 and NUDT4 are down-regulated (P < lt >; 0.05). Machine learning determines that LSM1, LARP1 and NCBP2 are high-performance diagnostic biomarkers, and the diagnostic values of the high-performance diagnostic biomarkers are verified by qRT-PCR and immunofluorescence in independent samples.

The invention discloses a circular non-coding RNA (Ribonucleic Acid) molecule circSENP6 and application thereof. The nucleotide sequence of the circSENP6 is shown as SEQ ID NO. 1. The invention also discloses a preparation method of the circular non-coding RNA molecule circSENP6. The circular non-coding RNA molecule circSENP6 can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can be used for early discovering coronary heart disease patients, reducing the death rate of coronary heart disease and improving the prognosis of patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

This invention belongs to the field of biomedicine, specifically relating to biomarkers and their applications for the clinical diagnosis of high-risk neuroblastoma. A product for the clinical diagnosis of high-risk neuroblastoma includes a reagent for detecting the expression level of the biomarker, which is a plasma exosomal protein called LAMP2. By detecting LAMP2 expression levels, this method can complement existing clinical indicators, enabling precise stratification and treatment of neuroblastoma, and also provides important guidance for the prognosis of children with tumors.

The present invention is applicable to the field of biomedical technologies and provides the use of EHD3 and ATP6V1E1 as markers for predicting the progression of periodontal disease and therapeutic targets. The present invention collects non-invasive and easily obtainable saliva samples from healthy individuals and patients clinically diagnosed with mild, moderate, and severe periodontitis, purifies the exosomes therein, and conducts proteomic sequencing studies. During the research process, the purified exosomes are identified, and then proteomic detection is carried out. By deeply analyzing the proteomic data, the present invention discovers two key proteins, namely EHD3 and ATP6V1E1, whose expression levels continuously increase as periodontitis progresses from mild to moderate to severe. These two proteins can accurately reflect the process of periodontal disease, and thus can be used as predictive and diagnostic biomarkers for the progression of different stages of periodontal disease, and also provide potential targets for the effective treatment of periodontal disease.

The application discloses a circRNA detection method based on Argonaute protein and rolling circle amplification. The method comprises the following steps: mixing a sample containing target circRNA to be detected with a specific reverse transcription primer and reverse transcriptase to obtain long-chain cDNA; mixing the obtained long-chain cDNA with pfAgo, gDNA and a DNA nucleic acid probe to carry out a reaction, and calculating the content of the target circRNA according to the fluorescence signal of the reaction mixture; the nucleotide sequence of the gDNA is specifically complementary to the cDNA sequence obtained by reverse transcription of the circRNA; the sequence of the DNA nucleic acid probe is specifically complementary to the sequence of the cDNA after one cutting of the cDNA by the pfAgo; and the DNA nucleic acid probe is a single-stranded DNA probe with a fluorescent label. The application can realize high-sensitivity, high-specificity and multiple target simultaneous analysis and detection of potential diagnostic biomarkers of liver cancer such as hsa_circ_0001445 and hsa_circ_0001141.

The instant disclosure relates to methods of treating sepsis by administering emapalumab. Also provided are diagnostic biomarkers for sepsis.

According to the application of the plasma exosome circRNA to the biomarker for early diagnosis of the lung adenocarcinoma, the plasma exosome marker circRNA is annular hsacirc0033861, hsacirc0043273 and hsacirc0011959, and the plasma exosome circRNA can be used as a biomarker for early diagnosis of the lung adenocarcinoma. The method comprises the following steps: firstly, constructing a circRNA / lncRNA-miRNA-mRNA regulation and control network in the plasma exosome on the basis of ceRNA microarray data and miRNA sequencing data of the exosome of a lung adenocarcinoma patient; according to the present invention, the lung adenocarcinoma patient specific plasma exosome with significant difference is screened by using a bioinformatics method so as to be adopted as the diagnosis marker, verification is performed in the lung adenocarcinoma patient through the reverse transcription real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), and the hsacirc0033861, the hsacirc0043273 and the hsacirc0011959 are finally screened, and can be used as the lung adenocarcinoma early diagnosis marker.

The invention discloses a circular non-coding RNA molecule hascirc0000799, which can be used as a diagnostic biomarker for coronary atherosclerosis, is used for biological identification and clinical detection of coronary atherosclerotic heart disease, and can find coronary heart disease patients at an early stage, reduce the death rate of the coronary heart disease and improve the prognosis of the patients by using the expression level of the gene for diagnosis. At present, the main diagnosis method for coronary atherosclerotic heart disease has the risks of high operation danger coefficient, large radiation and the like, and by collecting peripheral blood of a patient for detection, the method has the advantages of small trauma, good repeatability and the like, and is easier to accept.

A method of identifying oxidative stress caused by ageing and / or ultraviolet (UV) light exposure in a test cell. The method includes determining the methylation status of at least one CpG site in Protein Tyrosine Phosphatase Receptor Type N2 (PTPRN2), and / or the regulatory region of PTPRN2 in a DNA sample obtained from the test cell, and comparing the methylation status of the CpG site of PTPRN2 with that of a control without oxidative stress caused by ageing and / or UV light exposure. A difference in the methylation status of the CpG site of PTPRN2, and / or the regulatory region of PTPRN2 in the test cell compared to the CpG site in the control is indicative of the test cell having oxidative stress caused by exposure of the cell to UV light and / or ageing.

The invention discloses a tsRNA-SecTCA-L35 molecule and application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a colorectal cancer treatment target, and relates to the technical field of biological medicine. The invention provides application of the tsRNA-SecTCA-L35 molecule as a colorectal cancer diagnosis biomarker and a treatment target, in the diagnosis level, the molecule as a novel biomarker can be sensitively and specifically detected in samples such as plasma and tissue through qRT-PCR and other technologies, a brand new tool is provided for early discovery and non-invasive diagnosis of colorectal cancer, and the application of the tsRNA-SecTCA-L35 molecule as the colorectal cancer diagnosis biomarker and the treatment target is wide. In the aspect of treatment, by designing an analogue related to the molecular function and preparing the analogue into a pharmaceutical composition of a carrier such as lipidosome, the expression of the analogue in tumor cells can be effectively up-regulated, so that the proliferation of cancer cells is remarkably inhibited in vivo and in vitro, the death of the cancer cells is promoted, and the definite anti-tumor activity is shown; the important clinical application value is realized.

The invention belongs to the field of biological medicine, and particularly relates to a biomarker for clinical diagnosis of high-risk neuroblastoma and application of the biomarker. A product capable of being used for clinical diagnosis of high-risk neuroblastoma comprises a reagent for detecting the expression level of a biomarker, and the biomarker is plasma exosome protein CHD1. By detecting the CHD1 expression level, existing clinical indexes can be supplemented, precise layering and precise treatment of neuroblastoma are achieved, and meanwhile the kit has important guiding significance for prognosis judgment of tumor children.

The present invention is applicable to the field of biomedical technology and provides a diagnostic kit for unstable carotid atherosclerotic plaques. The present invention aims to collect urine samples from patients with carotid atherosclerotic plaques, perform proteomic mass spectrometry sequencing, and conduct comprehensive analysis in combination with transcriptomic and proteomic data of tissue samples. In this process, we successfully discovered two reliable diagnostic biomarkers: ADAMDEC1 and IQGAP2. These two biomarkers can not only be used to prepare diagnostic kits to achieve accurate diagnosis of unstable carotid atherosclerotic plaques, but also provide strong support for the judgment of disease prognosis. In addition, the discovery of the present invention has also opened up a new method for the diagnosis of carotid plaque stability and provided a more reliable basis for clinical prognosis evaluation and the identification of new therapeutic targets.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

The present invention firstly discloses a gene methylation biomarker combination and a screening model for the screening of high-grade cervical lesions. By comparing differentially methylated positions (DMPs) in normal tissues and high-grade lesion tissues, and using the corresponding CpG islands as diagnostic biomarkers for research, the present invention screens out 12 optimal CpG islands with consistent characteristics through a random forest classifier, and establishes a screening model based on the CpG island level of cervical exfoliated cells. This model can perform risk assessment on patients with positive HPV and negative cytology, distinguish high-risk groups from low-risk groups, and recommend different follow-up or intervention measures clinically to achieve patient stratification and effectively improve the accuracy of cervical cancer screening; the screening model has the advantages of high sensitivity and specificity, and objective risk assessment results.

This invention belongs to the field of biomedical technology, specifically relating to the application of plasma exosome biomarkers in the diagnosis and early warning of diabetic bladder dysfunction. This invention pioneered the use of 4D-DIA proteomics technology to conduct a comprehensive differential analysis of plasma exosome proteins from patients with diabetic bladder dysfunction (DBD). It successfully identified protein components with significantly different expression levels in the plasma exosomes of DBD patients, demonstrating significant value as potential diagnostic biomarkers. This invention is the first to propose that the detection of a four-protein combination in plasma exosomes (FCGR3B+THBS1+HLA-F+ATP5PB) can serve as a biomarker for diabetic bladder dysfunction (DBD) and also as an early warning indicator for the disease. This protein combination achieved an overall accuracy of 83.3% in identifying DBD.